Status:

COMPLETED

Repeat Nasal Allergen Challenge

Lead Sponsor:

Imperial College London

Collaborating Sponsors:

Novartis Pharmaceuticals

Conditions:

Hayfever

Eligibility:

All Genders

18-40 years

Phase:

PHASE2

Brief Summary

This is a non-drug, biomarker study to assess the utility of the model of repeated nasal allergen challenges in subjects with atopic rhinitis as a method of inducing an increased response to inhaled a...

Detailed Description

This is a non-drug, biomarker study to assess the utility of the model of repeated nasal allergen challenges in subjects with atopic rhinitis as a method of inducing an increased response to inhaled a...

Eligibility Criteria

Inclusion

  • Male and female subjects with a history of seasonal (intermittent) atopic rhinitis, aged 18-40 years.
  • Otherwise healthy with no health problems that may jeopardize the subjects participating in the study, absence of history of other significant allergies.

Exclusion

  • Smokers (use of tobacco products in the previous 3 months).
  • Presence of any respiratory disease other than a history of mild stable asthma not requiring treatment and associated with normal lung function (FEV1 \> 80% predicted at screening).

Key Trial Info

Start Date :

February 1 2006

Trial Type :

INTERVENTIONAL

End Date :

May 1 2006

Estimated Enrollment :

22 Patients enrolled

Trial Details

Trial ID

NCT00290368

Start Date

February 1 2006

End Date

May 1 2006

Last Update

September 14 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

National Heart & Lung Institute Clinical Studies Unit

London, United Kingdom, SW3 6HP